Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan

Ching-Yen Chen,1,2 Tze-Chun Tang,3 Tzu-Ting Chen,4 Ya Mei Bai,5,6 Huei-Huang Tsai,7 Hou-Liang Chen,7 Chun-Jen Huang,8,9 Chih-Ken Chen,1,2 Chun-Chih Chen,10 Mei-Chun Hsiao,11 Chia-Yih Liu,2,12 Hong-Shiow Yeh,13 Nan-Ying Chiu,10 Cheng-Chen Hsiao,14 Cheng-Sheng Chen,8,9 Tung-Ping Su5,15,16 1Department...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chen CY, Tang TC, Chen TT, Bai YM, Tsai HH, Chen HL, Huang CJ, Chen CK, Chen CC, Hsiao MC, Liu CY, Yeh HS, Chiu NY, Hsiao CC, Chen CS, Su TP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	prospective switch study open-label paliperidone extended release schizophrenia settings Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/f01c4f3aa2404eaab544b79cd04f56d2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f01c4f3aa2404eaab544b79cd04f56d2
record_format	dspace
institution	DOAJ
collection	DOAJ
language	EN
topic	prospective switch study open-label paliperidone extended release schizophrenia settings Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	prospective switch study open-label paliperidone extended release schizophrenia settings Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Chen CY Tang TC Chen TT Bai YM Tsai HH Chen HL Huang CJ Chen CK Chen CC Hsiao MC Liu CY Yeh HS Chiu NY Hsiao CC Chen CS Su TP Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
description	Ching-Yen Chen,1,2 Tze-Chun Tang,3 Tzu-Ting Chen,4 Ya Mei Bai,5,6 Huei-Huang Tsai,7 Hou-Liang Chen,7 Chun-Jen Huang,8,9 Chih-Ken Chen,1,2 Chun-Chih Chen,10 Mei-Chun Hsiao,11 Chia-Yih Liu,2,12 Hong-Shiow Yeh,13 Nan-Ying Chiu,10 Cheng-Chen Hsiao,14 Cheng-Sheng Chen,8,9 Tung-Ping Su5,15,16 1Department of Psychiatry, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan; 2School of Medicine, Chang Gung University, Taoyuan, Taiwan; 3Dr Tang’s Psychiatric Clinic, Kaohsiung, Taiwan; 4Department of Psychiatry, National Taiwan University Hospital, Yunlin Branch Hospital, Yunlin, Taiwan; 5Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan; 6Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan; 7Tsao Tun Psychiatric Center, Ministry of Health and Welfare, Nantou, Taiwan; 8Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 9Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 10Department of Psychiatry, Changhua Christian Hospital Lukang Branch Hospital, Changhua, Taiwan; 11Yong Mei Psychiatric Clinic, Taoyuan City, Taiwan; 12Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; 13Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan; 14Cheng Chen Hsiao Clinic, Chiayi, Taiwan; 15Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan; 16Department of Psychiatry, Cheng Hsin General Hospital, Taipei, Taiwan Purpose: Paliperidone extended release (ER) is an oral psychotropic treatment formulated to release paliperidone at a controlled, gradually ascending rate. We evaluated the efficacy and safety of switching to paliperidone ER in Taiwanese patients with schizophrenia who were unresponsive or intolerant to previous antipsychotic therapy.Patients and methods: This was a 24-week, open-label, single-arm, multicenter, Phase IV trial. Based on consulting psychiatrists’ judgment, patients were deemed eligible for the switch to paliperidone ER; the switch was achieved by cross-tapering, using a recommended starting dose of 6 mg. Eligibility considerations included lack of efficacy, tolerability, and/or adherence to previous oral antipsychotic medication. Results: Of the 297 enrolled patients, 178 (59.5%) completed the study. The main reasons for discontinuation included insufficient efficacy (8.7%), patient decision (8.4%), and adverse events (AEs; 6.4%). Improvements in the: Positive and Negative Syndrome Scale total score and Clinical Global Impression-Severity score were observed only in patients treated at medical centers and not in those treated at psychiatric hospitals. The most common AEs were insomnia, headache, constipation, and extrapyramidal syndrome. One or more serious AEs were reported in 11 (3.7%) patients; none resulted in death. No significant changes in body weight, plasma glucose, or lipid levels were observed.Conclusion: Switching to paliperidone ER was effective and well tolerated for up to 24 weeks in patients with schizophrenia who were unresponsive or intolerant to previous antipsychotic therapy. The observed differences in treatment between psychiatric hospitals and medical centers with regard to dosage and titration of paliperidone ER warrant further investigation. Keywords: prospective, switch study, open-label, paliperidone extended release, schizophrenia, settings
format	article
author	Chen CY Tang TC Chen TT Bai YM Tsai HH Chen HL Huang CJ Chen CK Chen CC Hsiao MC Liu CY Yeh HS Chiu NY Hsiao CC Chen CS Su TP
author_facet	Chen CY Tang TC Chen TT Bai YM Tsai HH Chen HL Huang CJ Chen CK Chen CC Hsiao MC Liu CY Yeh HS Chiu NY Hsiao CC Chen CS Su TP
author_sort	Chen CY
title	Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
title_short	Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
title_full	Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
title_fullStr	Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
title_full_unstemmed	Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
title_sort	efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in taiwan
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/f01c4f3aa2404eaab544b79cd04f56d2
work_keys_str_mv	AT chency efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT tangtc efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT chentt efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT baiym efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT tsaihh efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT chenhl efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT huangcj efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT chenck efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT chencc efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT hsiaomc efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT liucy efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT yehhs efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT chiuny efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT hsiaocc efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT chencs efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan AT sutp efficacytolerabilityandsafetyoforalpaliperidoneextendedreleaseinthetreatmentofschizophreniaa24weekopenlabelprospectiveswitchstudyindifferentsettingsintaiwan
_version_	1718402322579587072
spelling	oai:doaj.org-article:f01c4f3aa2404eaab544b79cd04f56d22021-12-02T02:41:37ZEfficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan1178-2021https://doaj.org/article/f01c4f3aa2404eaab544b79cd04f56d22018-03-01T00:00:00Zhttps://www.dovepress.com/efficacy-tolerability-and-safety-of-oral-paliperidone-extended-release-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Ching-Yen Chen,1,2 Tze-Chun Tang,3 Tzu-Ting Chen,4 Ya Mei Bai,5,6 Huei-Huang Tsai,7 Hou-Liang Chen,7 Chun-Jen Huang,8,9 Chih-Ken Chen,1,2 Chun-Chih Chen,10 Mei-Chun Hsiao,11 Chia-Yih Liu,2,12 Hong-Shiow Yeh,13 Nan-Ying Chiu,10 Cheng-Chen Hsiao,14 Cheng-Sheng Chen,8,9 Tung-Ping Su5,15,16 1Department of Psychiatry, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan; 2School of Medicine, Chang Gung University, Taoyuan, Taiwan; 3Dr Tang’s Psychiatric Clinic, Kaohsiung, Taiwan; 4Department of Psychiatry, National Taiwan University Hospital, Yunlin Branch Hospital, Yunlin, Taiwan; 5Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan; 6Department of Psychiatry, College of Medicine, National Yang-Ming University, Taipei, Taiwan; 7Tsao Tun Psychiatric Center, Ministry of Health and Welfare, Nantou, Taiwan; 8Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 9Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 10Department of Psychiatry, Changhua Christian Hospital Lukang Branch Hospital, Changhua, Taiwan; 11Yong Mei Psychiatric Clinic, Taoyuan City, Taiwan; 12Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; 13Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan; 14Cheng Chen Hsiao Clinic, Chiayi, Taiwan; 15Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan; 16Department of Psychiatry, Cheng Hsin General Hospital, Taipei, Taiwan Purpose: Paliperidone extended release (ER) is an oral psychotropic treatment formulated to release paliperidone at a controlled, gradually ascending rate. We evaluated the efficacy and safety of switching to paliperidone ER in Taiwanese patients with schizophrenia who were unresponsive or intolerant to previous antipsychotic therapy.Patients and methods: This was a 24-week, open-label, single-arm, multicenter, Phase IV trial. Based on consulting psychiatrists’ judgment, patients were deemed eligible for the switch to paliperidone ER; the switch was achieved by cross-tapering, using a recommended starting dose of 6 mg. Eligibility considerations included lack of efficacy, tolerability, and/or adherence to previous oral antipsychotic medication. Results: Of the 297 enrolled patients, 178 (59.5%) completed the study. The main reasons for discontinuation included insufficient efficacy (8.7%), patient decision (8.4%), and adverse events (AEs; 6.4%). Improvements in the: Positive and Negative Syndrome Scale total score and Clinical Global Impression-Severity score were observed only in patients treated at medical centers and not in those treated at psychiatric hospitals. The most common AEs were insomnia, headache, constipation, and extrapyramidal syndrome. One or more serious AEs were reported in 11 (3.7%) patients; none resulted in death. No significant changes in body weight, plasma glucose, or lipid levels were observed.Conclusion: Switching to paliperidone ER was effective and well tolerated for up to 24 weeks in patients with schizophrenia who were unresponsive or intolerant to previous antipsychotic therapy. The observed differences in treatment between psychiatric hospitals and medical centers with regard to dosage and titration of paliperidone ER warrant further investigation. Keywords: prospective, switch study, open-label, paliperidone extended release, schizophrenia, settings Chen CYTang TCChen TTBai YMTsai HHChen HLHuang CJChen CKChen CCHsiao MCLiu CYYeh HSChiu NYHsiao CCChen CSSu TPDove Medical Pressarticleprospectiveswitch studyopen-labelpaliperidone extended releaseschizophreniasettingsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 725-732 (2018)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan

Ejemplares similares